Purple Biotech Identifies Oncology Biomarker Linked to 79% PFS Reduction
Ticker: PPBT · Form: 6-K · Filed: Nov 4, 2024 · CIK: 1614744
Sentiment: bullish
Topics: biomarker, oncology, clinical-trial-data
TL;DR
Purple Biotech found a biomarker that shows CM24 treatment cuts progression by 79% - big news for cancer drug.
AI Summary
On November 4, 2024, Purple Biotech Ltd. announced the identification of a potential new serum biomarker for its lead oncology therapeutic candidate, CM24. This biomarker is associated with a significant 79% reduction in progression-free survival (PFS) in patients treated with CM24. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel.
Why It Matters
Identifying predictive biomarkers can help select patients most likely to benefit from CM24, potentially improving trial success rates and accelerating the drug's path to market.
Risk Assessment
Risk Level: medium — Biomarker identification is an early step; clinical validation and regulatory approval are still required, carrying inherent development risks.
Key Numbers
- 79% — PFS Reduction (Associated with the identified biomarker when treated with CM24)
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- CM24 (drug_candidate) — Lead oncology therapeutic candidate
- Kitov Pharma Ltd. (company) — Former company name
- November 4, 2024 (date) — Announcement date
- 79% (percentage) — Associated reduction in progression-free survival
FAQ
What is the specific nature of the newly identified serum biomarker?
The filing does not specify the exact nature of the biomarker, only that it is a potential new serum biomarker.
In which patient population was the 79% reduction in progression-free survival observed?
The reduction was observed in patients treated with Purple Biotech's lead oncology therapeutic candidate, CM24.
What is the primary therapeutic area for CM24?
CM24 is described as a lead oncology therapeutic candidate, indicating its use in cancer treatment.
When was this announcement made by Purple Biotech Ltd.?
The announcement was made on November 4, 2024.
What was Purple Biotech Ltd. formerly known as?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd.
Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-11-04 07:51:03
Filing Documents
- ea0219810-6k_purple.htm (6-K) — 14KB
- ea021981001ex99-1_purple.htm (EX-99.1) — 13KB
- 0001213900-24-093751.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. November 4, 2024 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2